The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

ClinicalTrials & Tribulations

As cancer patients use AI chatbots, dangers lurk—but new safeguards can help

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

Patients affected by cancer are increasingly turning to artificial intelligence-powered chatbots, such as ChatGPT and Gemini, for answers to pressing health questions. These tools, available around the clock and free from geographic or scheduling constraints, are appealing when access to medical professionals is limited by financial, language, logistical, or emotional barriers. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Ghulam Rasool, PhD
Assistant member, Department of Machine Learning, H. Lee Moffitt Cancer Center & Research Institute
Brian D. Gonzalez, PhD
Associate center director for research career development, Associate member, Department of Health Outcomes & Behavior, H. Lee Moffitt Cancer Center & Research Institute
Katherine Chung-Bridges, MD, MPH
Chief community research officer, Health Choice Network
Table of Contents

YOU MAY BE INTERESTED IN

Guest Editorial

The defining question of the next decade is not how many drug candidates can be generated, but who decides which ones move forward, and why
Drug development must convene a forum for candid, cross-sector discussion

At the 2026 Annual Meeting of the American Society of Clinical Oncology in Chicago, results from the phase III HARMONi-6 trial were presented at the plenary session and published simultaneously in The Lancet. The HARMONi-6 trial tested a novel bispecific antibody that engages PD-1 and VEGF (ivonescimab), given with platinum-doublet chemotherapy to patients with previously untreated advanced squamous non-small cell lung cancer. 
By Richard L. Schilsky, H. Kim Lyerly, Thomas R. Fleming and Renzo Canetta
ClinicalGuest Editorial

Like it or not, AI psycho-oncology care is already happening. Urgently needed: An ethical framework
Developers and mental health providers must share the same goal: Safe, equitable, trustworthy, and patient-centered care

In 2026, more than 900 million people are estimated to be regularly using generative artificial intelligence—computer systems capable of creating human-like text, images, audio, video, and other original content. AI is becoming integrated into nearly every aspect of daily life. Health care is no exception. 
By Viktor Clark, Sean M. Dozier, AnnaLynn M. Williams, Cynthia M. Rand and Lee A. Kehoe
Byline
Ghulam Rasool, PhD
Assistant member, Department of Machine Learning, H. Lee Moffitt Cancer Center & Research Institute
Brian D. Gonzalez, PhD
Associate center director for research career development, Associate member, Department of Health Outcomes & Behavior, H. Lee Moffitt Cancer Center & Research Institute
Katherine Chung-Bridges, MD, MPH
Chief community research officer, Health Choice Network
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account